AEON Biopharma, Inc. SEC filings AEON
AEON Biopharma, Inc. has 361 filings in SEC EDGAR's recent list, going back to Dec 23, 2020. Its latest annual report, Form ARS, was filed on Apr 29, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 3, 2026 (material agreement). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Jul 13, 2026 | — |
| DRS | Filing | May 29, 2026 | — |
| EFFECT | Filing | Feb 17, 2026 | — |
| CORRESP | Letter to the SEC | Feb 12, 2026 | — |
| UPLOAD | Letter from the SEC | Feb 12, 2026 | — |
| DEFR14A | Filing | Jun 11, 2025 | — |
| UPLOAD | Letter from the SEC | Feb 28, 2025 | — |
| EFFECT | Filing | Aug 21, 2024 | — |
| CORRESP | Letter to the SEC | Aug 20, 2024 | — |
| UPLOAD | Letter from the SEC | Aug 19, 2024 | — |
| EFFECT | Filing | Aug 5, 2024 | — |
| CORRESP | Letter to the SEC | Aug 2, 2024 | — |
| CORRESP | Letter to the SEC | Jul 23, 2024 | — |
| UPLOAD | Letter from the SEC | Jul 16, 2024 | — |
| CORRESP | Letter to the SEC | Jul 9, 2024 | — |
| UPLOAD | Letter from the SEC | Jun 28, 2024 | — |
| UPLOAD | Letter from the SEC | Jun 27, 2024 | — |
| CORRESP | Letter to the SEC | May 31, 2024 | — |
| ARS/A | Filing | May 14, 2024 | Dec 31, 2023 |
| UPLOAD | Letter from the SEC | Apr 30, 2024 | — |
| 25-NSE | Delisting notice | Apr 29, 2024 | — |
| CORRESP | Letter to the SEC | Apr 2, 2024 | — |
| CORRESP | Letter to the SEC | Feb 27, 2024 | — |
| UPLOAD | Letter from the SEC | Dec 20, 2023 | — |
| CORRESP | Letter to the SEC | Nov 22, 2023 | — |
| UPLOAD | Letter from the SEC | Nov 15, 2023 | — |
| CORRESP | Letter to the SEC | Oct 20, 2023 | — |
| UPLOAD | Letter from the SEC | Sep 8, 2023 | — |
| DEL AM | Filing | Aug 22, 2023 | — |
| CERT | Nyse american certification | Jul 21, 2023 | — |
| 25 | Filing | Jul 21, 2023 | — |
| 8-A12B | Filing | Jul 21, 2023 | — |
| 425 | Filing | Jul 17, 2023 | — |
| 425 | Filing | Jul 12, 2023 | — |
| 425 | Filing | Jul 5, 2023 | — |
| 425 | Filing | Jun 30, 2023 | — |
| 425 | Filing | Jun 30, 2023 | — |
| 425 | Filing | May 24, 2023 | — |
| NT 10-Q | Filing | May 15, 2023 | Mar 31, 2023 |
| EFFECT | Filing | May 12, 2023 | — |
| CORRESP | Letter to the SEC | May 11, 2023 | — |
| CORRESP | Letter to the SEC | May 9, 2023 | — |
| UPLOAD | Letter from the SEC | May 8, 2023 | — |
| 425 | Filing | May 1, 2023 | — |
| CORRESP | Letter to the SEC | May 1, 2023 | — |
| UPLOAD | Letter from the SEC | Mar 23, 2023 | — |
| CORRESP | Letter to the SEC | Mar 9, 2023 | — |
| UPLOAD | Letter from the SEC | Feb 27, 2023 | — |
| 425 | Filing | Feb 24, 2023 | — |
| 425 | Filing | Feb 14, 2023 | — |
| CORRESP | Letter to the SEC | Feb 9, 2023 | — |
| UPLOAD | Letter from the SEC | Jan 27, 2023 | — |
| UPLOAD | Letter from the SEC | Jan 26, 2023 | — |
| 425 | Filing | Jan 11, 2023 | — |
| 425 | Filing | Jan 10, 2023 | — |
| 425 | Filing | Dec 27, 2022 | — |
| UPLOAD | Letter from the SEC | Dec 23, 2022 | — |
| CORRESP | Letter to the SEC | Dec 21, 2022 | — |
| 425 | Filing | Dec 21, 2022 | — |
| UPLOAD | Letter from the SEC | Dec 19, 2022 | — |
| 425 | Filing | Dec 13, 2022 | — |
| NT 10-Q | Filing | May 17, 2021 | Mar 31, 2021 |
| EFFECT | Filing | Feb 8, 2021 | — |
| CERT | Filing | Feb 8, 2021 | — |
| 8-A12B | Form 8-a12b | Feb 8, 2021 | — |
| DRS | Filing | Dec 23, 2020 | — |
Showing 66 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AEON (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Aliso Viejo, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1837607
- Former names
- Priveterra Acquisition Corp. (until Jul 24, 2023)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.